The Addario Lung Cancer Medical Institute (ALCMI, voiced as “Alchemy”), founded in 2008 as a 501(c)(3) non-profit organization by lung cancer survivor Bonnie J. Addario, is a patient-centric, international research consortium driving research otherwise not possible. Working in tandem with its “partner” foundation the Bonnie J. Addario Lung Cancer Foundation (ALCF), ALCMI powers collaborative initiatives in genetic (molecular) testing, therapeutic discoveries, targeted treatments and early detection. ALCMI overcomes barriers to collaboration via a world-class team of investigators from 26 member institutions in the USA, UK, and Europe, supported by dedicated, centralized research infrastructures such as standardized biorepositories and data systems. ALCMI directly facilitates research by combining scientific expertise found at leading academic institutions with patient access through its network of community cancer centers – accelerating novel research advancements to lung cancer patients. By providing access to critical masses of patient stakeholders, academic, community and industry researchers, ALCMI and ALCF are making progress towards their shared goal of transforming lung cancer into a chronically managed disease by 2023.